
    
      COLUMBIA-1 is a Phase 1b/2, open-label, multicenter, randomized, multidrug platform study to
      evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) in combination
      with novel oncology therapies in patients with first-line metastatic MSS-CRC. The study is
      designed to concurrently evaluate potential novel combinations with clinical promise using a
      2-part approach. Part 1 is a Phase 1b study of safety, and Part 2 is a Phase 2 study of
      efficacy and safety.
    
  